📣 VC round data is live. Check it out!
- Public Comps
- BICO Group
BICO Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for BICO Group and similar public comparables like NN, Nyxoah, EKF Diagnostics, Apyx Medical and more.
BICO Group Overview
About BICO Group
BICO Group AB is a bio-convergence company. The company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Group consists of three reporting segments: Bioprinting, Life Science Solutions, and Lab Automation. Bioprinting consists of CELLINK, MatTek, Visikol, and Advanced BioMatrix. Life Science Solutions consists of CYTENA, DISPENDIX, Discover Echo, QInstruments, SCIENION, and Cellenion. Lab Automation consists of Biosero.
Founded
2000
HQ

Employees
726
Website
Financials (LTM)
EV
$139M
Valuation Multiples
Start free trialBICO Group Financials
BICO Group reported last 12-month revenue of $170M and EBITDA of $4M.
In the same LTM period, BICO Group generated $89M in gross profit, $4M in EBITDA, and had net loss of ($122M).
Revenue (LTM)
BICO Group P&L
In the most recent fiscal year, BICO Group reported revenue of $171M and EBITDA of $2M.
BICO Group is unprofitable as of last fiscal year, with gross margin of 49%, EBITDA margin of 1%, and net margin of (69%).
Financial data powered by Morningstar, Inc.
BICO Group Stock Performance
BICO Group has current market cap of $145M, and enterprise value of $139M.
Market Cap Evolution
BICO Group's stock price is $2.05.
BICO Group share price decreased by 11.4% in the last 30 days, and by 47.2% in the last year.
BICO Group has an EPS (earnings per share) of $-1.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $139M | $145M | -4.4% | -11.4% | 2.6% | -47.2% | $-1.66 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBICO Group Valuation Multiples
BICO Group trades at 0.8x EV/Revenue multiple, and 31.6x EV/EBITDA.
EV / Revenue (LTM)
BICO Group Financial Valuation Multiples
As of May 9, 2026, BICO Group has market cap of $145M and EV of $139M.
BICO Group has a P/E ratio of (1.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BICO Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


BICO Group Margins & Growth Rates
BICO Group decreased revenue by 0% but EBITDA grew by 314% in the last fiscal year.
In the most recent fiscal year, BICO Group reported gross margin of 49%, EBITDA margin of 1%, and net margin of (69%).
BICO Group Margins
BICO Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
BICO Group Operational KPIs
BICO Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
BICO Group's Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BICO Group's Rule of X is 18% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
BICO Group Competitors
BICO Group competitors include NN, Nyxoah, EKF Diagnostics, Apyx Medical, Biodesix, Edap TMS, Quanterix, SANUWAVE Health, Treace Medical Concepts and JETEMA Co..
Most BICO Group public comparables operate across Medical Devices, Laboratory Services, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.8x | 0.8x | 7.1x | 6.9x | |||
| 11.1x | 6.2x | (1.5x) | (1.4x) | |||
| 2.0x | 1.9x | 8.0x | 7.9x | |||
| 3.1x | 2.9x | (42.6x) | (41.6x) | |||
| 2.3x | 2.1x | (11.5x) | (13.4x) | |||
| 2.2x | 2.2x | (7.4x) | (7.2x) | |||
| 0.5x | 0.5x | (1.5x) | (1.8x) | |||
| 3.3x | 3.1x | 7.4x | — | |||
This data is available for Pro users. Sign up to see all BICO Group competitors and their valuation data. Start Free Trial | ||||||
BICO Group M&A Activity
BICO Group has acquired 4 companies to date.
Last acquisition by BICO Group was on May 6th 2022. BICO Group acquired Allegro 3D for $11M (EV/Revenue multiple of ).
Latest Acquisitions by BICO Group
| Description | Allegro 3D is a bioprinting technology company specializing in Digital Light Processing systems for biomedical applications. Headquartered in Hauppauge, New York, it produces high-resolution printers for fabricating tissues, scaffolds, and drug screening devices used in regenerative medicine and pharmaceutical research. | Biosero is a San Diego-based lab automation provider delivering Green Button Go software for workcell orchestration. Hardware-agnostic, it integrates pipetting robots, shakers, and analyzers from vendors like Hamilton and Tecan, executing protocols 10x faster. Founded in 2016, Biosero supports 200 biopharma clients including Amgen, optimizing high-throughput screening and NGS workflows across 50 facilities. | QInstruments is a Jena-based leader in mixing technology for life sciences, serving research labs, university medical centers, and drug discovery facilities in pharmaceuticals and biotechnology. Founded in 2003, it supplies automated pipetting systems, shakers, and laboratory automation tools for precise sample handling in high-throughput environments across Europe. | Advanced BioMatrix is a San Diego-based leader in 3D cell culture matrices for tissue engineering, bioprinting, and assays. Producing over 50 products including RGD peptides, collagen, and hyaluronic acid hydrogels, it supplies research institutions like UC San Diego with lot-consistent materials tested for sterility and bioactivity. Operating for more than 15 years, the company enables stem cell proliferation and organoid models used in regenerative medicine studies. |
| HQ Country | ||||
| HQ City | San Diego, CA | San Diego, CA | Jena | San Diego, CA |
| Deal Date | 6 May 2022 | 16 Dec 2021 | 1 Oct 2021 | 27 Aug 2021 |
| Valuation | $11M | $165M | $66M | $15M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all BICO Group acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BICO Group
| When was BICO Group founded? | BICO Group was founded in 2000. |
| Where is BICO Group headquartered? | BICO Group is headquartered in Sweden. |
| How many employees does BICO Group have? | As of today, BICO Group has over 726 employees. |
| Who is the CEO of BICO Group? | BICO Group's CEO is Maria Forss. |
| Is BICO Group publicly listed? | Yes, BICO Group is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of BICO Group? | BICO Group trades under BICO ticker. |
| When did BICO Group go public? | BICO Group went public in 2016. |
| Who are competitors of BICO Group? | BICO Group main competitors include NN, Nyxoah, EKF Diagnostics, Apyx Medical, Biodesix, Edap TMS, Quanterix, SANUWAVE Health, Treace Medical Concepts, JETEMA Co.. |
| What is the current market cap of BICO Group? | BICO Group's current market cap is $145M. |
| What is the current revenue of BICO Group? | BICO Group's last 12 months revenue is $170M. |
| What is the current revenue growth of BICO Group? | BICO Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of BICO Group? | Current revenue multiple of BICO Group is 0.8x. |
| Is BICO Group profitable? | Yes, BICO Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BICO Group? | BICO Group's last 12 months EBITDA is $4M. |
| What is BICO Group's EBITDA margin? | BICO Group's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of BICO Group? | Current EBITDA multiple of BICO Group is 31.6x. |
| What is the current FCF of BICO Group? | BICO Group's last 12 months FCF is ($16M). |
| What is BICO Group's FCF margin? | BICO Group's last 12 months FCF margin is (9%). |
| What is the current EV/FCF multiple of BICO Group? | Current FCF multiple of BICO Group is (8.8x). |
| How many companies BICO Group has acquired to date? | As of May 2026, BICO Group has acquired 4 companies. |
| What was the largest acquisition by BICO Group? | $165M acquisition of Biosero on 16th December 2021 was the largest M&A BICO Group has done to date. |
| What companies BICO Group acquired? | BICO Group acquired Biosero, QInstruments, Advanced Biomatrix, and Allegro 3D. |
| In how many companies BICO Group has invested to date? | BICO Group hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to BICO Group
Lists including BICO Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

